Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Fosun Pharma's FCN-159 and FCN-437c Win NMPA Marketing Approvals
Fosun PharmaceuticalHKG: 2196

Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals

Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013
ADC / XDCHengrui Pharmaceuticals

Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013

NMPA Approves Mabwell's 8MW0511 for Febrile Neutropenia Prevention
Mabwell BioscienceProduct approvals

NMPA Approves Mabwell’s 8MW0511 for Febrile Neutropenia Prevention

Hinova's Deutenzalutamide Approved for Metastatic Prostate Cancer in China
Hinova PharmaceuticalsProduct approvals

Hinova’s Deutenzalutamide Approved for Metastatic Prostate Cancer in China

Show More